NCT02151084 2025-12-16
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
University Health Network, Toronto
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT07025174 2025-06-17
SAIB
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT05712356 2025-06-06
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Active not recruiting
NCT03260712 2023-11-03
Pembrolizumab in Biliary Tract Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03473574 2023-06-15
IMMUCHEC
AIO-Studien-gGmbH
Phase 2 Completed
NCT02392637 2022-02-02
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02631590 2021-08-04
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00832637 2018-06-29
Gem-ox
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01151761 2016-07-29
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Stanford University
Phase 2 Terminated
NCT00919061 2016-02-03
Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00123825 2007-12-21
Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer
Dana-Farber Cancer Institute
Phase 2 Completed